AG 6840

Drug Profile

AG 6840

Latest Information Update: 21 Sep 2006

Price : $50

At a glance

  • Originator Agouron Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Rhinovirus 3C protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Common cold

Most Recent Events

  • 21 Sep 2006 Discontinued - Preclinical for Rhinovirus infections in USA (unspecified route)
  • 20 Jul 2000 Profile reviewed but no significant changes made
  • 22 Jun 2000 Warner-Lambert has merged with Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top